Literature DB >> 1656551

The monoclonal HBA-71 antibody modulates proliferation of thymocytes and Ewing's sarcoma cells by interfering with the action of insulin-like growth factor I.

G Hamilton1, R Mallinger, S Hofbauer, M Havel.   

Abstract

The monoclonal HBA-71 antibody recognizes a Ewing's sarcoma associated antigen, which is also highly expressed on the cell surface of human cortical thymocytes and islets of Langerhans among normal tissues. The antibody was found to inhibit partially the growth of ES tumor cell lines and to trigger proliferation in thymocyte cultures. The influence of growth factors and the effect of the HBA-71 antibody was further investigated in the present study. The growth of ES tumor cells was demonstrated to be dependent on the presence of insulin-like growth factor I or insulin. The HBA-71 antibody (25 micrograms/ml) enhanced the growth stimulatory effect of IGF-I under serum-free conditions. The expression of the HBA-71 epitope is modulated positively by IGF-I and insulin and negatively by dexamethasone and human growth hormone in ES/PNET tumor cells and thymocytes. IGF-I either alone or in combination with HBA-71 stimulated the proliferation of thymocytes under serum-free conditions whereas in complete medium, IGF-I stimulated thymidine incorporation and the HBA-71 antibody either alone or in the presence of IGF-I showed inhibitory activity most likely due to down-regulation of the receptor. These data demonstrate the important role of IGF-I in the growth of ES/PNET tumor cells as well in the proliferative activity of HBA-71 positive normal thymocytes. The biological activity of IGF-I in malignant thymocytes, pancreas tumors, fetal muscle, brain, granulosa and Sertoli cells has been documented in the literature.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1656551

Source DB:  PubMed          Journal:  Thymus        ISSN: 0165-6090


  7 in total

Review 1.  Recent advances in the molecular pathogenesis of Ewing's sarcoma.

Authors:  E C Toomey; J D Schiffman; S L Lessnick
Journal:  Oncogene       Date:  2010-06-14       Impact factor: 9.867

Review 2.  The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas.

Authors:  Sushma Vemulapalli; Alain Mita; Yesid Alvarado; Kamalesh Sankhala; Monica Mita
Journal:  Target Oncol       Date:  2011-04-28       Impact factor: 4.493

3.  Insulin-like growth factor 1 receptor as a therapeutic target in ewing sarcoma: lack of consistent upregulation or recurrent mutation and a review of the clinical trial literature.

Authors:  Alison O'Neill; Nilay Shah; Naamah Zitomersky; Marc Ladanyi; Neerav Shukla; Aykut Uren; David Loeb; Jeffrey Toretsky
Journal:  Sarcoma       Date:  2013-01-28

Review 4.  Role of immunotherapy in Ewing sarcoma.

Authors:  Erin Morales; Michael Olson; Fiorella Iglesias; Saurabh Dahiya; Tim Luetkens; Djordje Atanackovic
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

5.  Potential molecular targets for Ewing's sarcoma therapy.

Authors:  Babu Jully; Thangarajan Rajkumar
Journal:  Indian J Med Paediatr Oncol       Date:  2012-10

6.  The role of insulin-like growth factor system in soft tissue sarcomas: from physiopathology to targeted therapeutic approaches.

Authors:  W Zumkeller
Journal:  Sarcoma       Date:  1998

7.  PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.

Authors:  Chiara Giorgi; Aleksandar Boro; Florian Rechfeld; Laura A Lopez-Garcia; Maria E Gierisch; Beat W Schäfer; Felix K Niggli
Journal:  Oncotarget       Date:  2015-10-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.